Phase 2 of REFLECT Trial Begins for Keystone Heart’s TriGuard 3 Embolic Protection Device

 

June 18, 2018—Keystone Heart Ltd. recently announced the launch of phase 2 of the REFLECT trial to evaluate the safety and efficacy of the company's next-generation TriGuard 3 cerebral embolic protection device for use during transcatheter aortic valve replacement (TAVR). Keystone Heart is headquartered in Israel with United States operations in Tampa, Florida.

REFLECT is a multicenter, prospective, randomized, clinical study designed to assess the safety and efficacy of comprehensive cerebral protection from emboli released during cardiovascular procedures.

According to the company, phase 1 of the REFLECT trial, which remains blinded, enrolled 258 patients and utilized the TriGuard HDH, an earlier-generation device that has received CE Mark approval in the European Union.

In Keystone Heart's announcement, REFLECT study chairman Jeffrey Moses, MD, stated that enrollment has been initiated for up to 275 additional patients in phase 2 of the trial. Dr. Moses advised that this trial is designed to definitively address the role of comprehensive cerebral embolic protection in improving the safety of the TAVR procedure. Trial completion is targeted for October 2018 and will be followed by submission to the US Food and Drug Administration. Currently, the TriGuard 3 device is for investigational use only, and is not yet commercially available in the United States.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.